Baxter(US:BAX) Globenewswire·2025-11-04 16:43Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device, which reportedly suffered systemic defects leading to serious patient risks [4][6]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that caused malfunctions, including underinfusion and overinfusion, which posed risks of serious injury or death to patients [6]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm to patients [6]. - The company’s statements about the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading based on the undisclosed risks and defects [6]. Group 2: Impact on Stock and Legal Proceedings - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, which resulted in a 22.4% drop in stock price, closing at $21.76 [7]. - Investors who suffered losses exceeding $10,000 between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [4][9].